CD4 and urinary bladder cancer: Similarly, a group of efficiently responsive CD4+ICOS+ (inducible co‐stimulator) T cells is identified as a phenotype of Th1 cells in bladder cancer patients who are all treated with Ipilimumab (anti‐CTLA‐4).